Olopatadine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Ophth Allergic conjunctivitis As 0.1% soln: 1 drop in the affected eye(s) bid at an interval of 6-8 hr. As 0.2% soln: 1 drop in the affected eye(s) once daily. Nasal Seasonal allergic rhinitis As 0.6% spray: 2 sprays into each nostril bid.
Dosage Details
Nasal
Seasonal allergic rhinitis
Adult: As 0.6% spray: 2 sprays into each nostril bid.
Child: 6-11 year 1 spray into each nostril bid.

Ophthalmic
Allergic conjunctivitis
Adult: As 0.1% soln: 1 drop in the affected eye(s) bid at an interval of 6-8 hr. As 0.2% soln: 1 drop in the affected eye(s) once daily.
Child: ≥3 yr Same as adult dose.
Special Precautions
Not intended for contact lens-related irritation (ophth). Patient w/ other nasal disease. Pregnancy and lactation.
Adverse Reactions
Headache, somnolence. Symptoms similar to cold syndrome and pharyngitis, blurred vision, ocular burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid oedema, or ocular pain or pruritus. Nasal: Bitter taste, epistaxis, pyrexia, rash, nasal ulceration and septal perforation, pharyngolaryngeal pain, postnasal drip, cough, UTI, upper resp tract infection.
Patient Counseling Information
May impair ability to engage in activities requiring complete mental alertness and motor coordination (e.g. driving or operating machinery) after admin of the nasal spray. Ophth: Remove contact lenses prior to eye admin. Reinsert contact lenses 10 min after admin. Do not wear contact lenses if eyes are red. Improper handling may contaminate soln w/ bacteria that may cause ocular infections. Tip of the dispensing container should not be in contact w/ eye, eyelids or surrounding structures.
MonitoringParameters
Nasal examinations should be performed periodically for signs of adverse effects on the nasal mucosa.
Overdosage
Symptoms: Drowsiness in adults and, initially, agitation and restlessness, followed by drowsiness in childn. Management: Symptomatic or supportive treatment.
Drug Interactions
May result in additive CNS depression w/ CNS depressants.
Food Interaction
Concomitant use w/ alcohol may result in additive CNS depression (nasal).
Action
Description: Olopatadine is a relatively selective histamine H1-receptor antagonist which inhibits the release of histamine from mast cells and histamine-induced effects on conjunctival epithelial cells. It shares many of the pharmacologic effects of mast cell stabilisers.
Onset: 30 min (nasal).
Pharmacokinetics:
Absorption: Ophth: Minimal. Bioavailability: 57% (nasal). Time to peak plasma concentration: 15 min to 2 hr (nasal).
Distribution: Plasma protein binding: Approx 55% (mainly albumin).
Metabolism: Not extensively metabolised.
Excretion: Via urine (60-70% as unchanged drug); faeces (approx 17%). Elimination half-life: 8-12 hr.
Storage
Store below 25°C.
References
Anon. Olopatadine (Nasal) Drug Information. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/03/2014.

Anon. Olopatadine (Ophthalmic) Drug Information. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/03/2014.

Buckingham R (ed). Olopatadine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/03/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Olopatadine. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 03/03/2014.

Patanase Spray, Metered (Alcon Laboratories). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 03/03/2014.

Disclaimer: This information is independently developed by MIMS based on Olopatadine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in